Skip to main content

Table 3 Numbers of subjects who had neutralizing antibody levels above the 30% inhibition threshold

From: Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine

 

All (N = 46)

ChAdOx-1 group

(N = 24)

BNT162b2 group

(N = 22)

Before boosting

Before boosting

4 weeks after boosting

p value

Before boosting

4 weeks after boosting

p value

Wild type

35 (76.1)

19 (79.2)

24 (100.0)

0.062

16 (72.7)

22 (100.0)

0.031

Alpha (B.1.1.7)

33 (71.7)

16 (66.7)

24 (100.0)

0.008

17 (77.3)

22 (100.0)

0.062

Beta (B.1.351)

7 (15.2)

0 (0)

24 (100.0)

< 0.001

7 (31.8)

22 (100.0)

< 0.001

Delta (B.1.617.2)

30 (65.2)

14 (58.3)

24 (100.0)

0.002

16 (72.7)

22 (100.0)

0.031

Omicron (B.1.1.529)

1 (2.2)

0 (0)

10 (41.7)

0.002

1 (4.5)

12 (54.5)

0.001

  1. Data are presented as N (%)
  2. The numbers of elderly health care workers who had levels of neutralizing antibodies against the SARS-CoV-2 wild-type, Alpha, Beta, Delta, and Omicron variants above the 30% inhibition threshold before and 4 weeks after boosting with the ChAdOx-1 and BNT162b2 vaccines
Back to article page

Immunity & Ageing

ISSN: 1742-4933

Contact us